Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Status:
Terminated
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lirilumab and Opdivo (nivolumab),
alone or in combination with Vidaza (azacitidine), can help to control MDS. The safety of
these drug combinations will also be studied.
This is an investigational study. Lirilumab is not FDA approved or commercially available. It
is currently being used for research purposes. Nivolumab is FDA approved and commercially
available for the treatment of melanoma and non small cell lung cancer (NSCLC). Azacitidine
is FDA approved and commercially available for the treatment of MDS. The study doctor can
explain how the study drugs are designed to work.
Up to 80 participants will be enrolled in this study. All will take part at MD Anderson.